Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

(2011) Vasundhara Kain et al.   Cardiovascular Diabetology

Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats

(2011) Bingong Li et al.   Cardiovascular Diabetology

Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment

(2011) Inês Falcão-Pires et al.   HEART FAILURE REVIEWS

Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage

(2010) Vasundhara Kain et al.   Cardiovascular Diabetology

Diabetic cardiomyopathy, causes and effects

(2010) Sihem Boudina et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Dominant-negative p38α mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus

(2009) Rajarajan A. Thandavarayan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Antioxidant Properties of an Endogenous Thiol: Alpha-lipoic Acid, Useful in the Prevention of Cardiovascular Diseases

(2009) Stéliana Ghibu et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options

(2008) Ashish Aneja et al.   AMERICAN JOURNAL OF MEDICINE

Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy

(2008) Sophie Linthout et al.   BASIC RESEARCH IN CARDIOLOGY

Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats

(2008) Wenyuan Zhao et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY